WEHI-345

WEHI-345

W651350-5mg

5mg

≥98%

-20°C储存

超低温冰袋运输

WEHI-345 is a potent and selective RIPK2 kinase inhibitor with an IC 50 of 0.13 μM, which delays RIPK2 ubiquitylation and NF-κB activation on oligomerization domain (NOD) stimulation In Vitro WEHI-345 (500 nM; Raw 267.4 cells) is able to inhibit MDP-induced autophosphorylation activity of RIPK2 in cells. WEHI-345 (500 nM; 0 hour, 2 hours, 4 hours, 8 hours; BMDMs or THP-1 cells) potently blocks MDP-induced transcription of the inflammatory mediators TNF and interleukin-6 (IL-6) in bone marrow-derived macrophages (BMDMs). In THP-1 cells, WEHI-345 reduces mRNA levels of NF-kB targets such as TNF, IL-8, IL-1b and A20. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: Raw 267.4 cells Concentration: 500 nM Incubation Time: Result: Inhibited MDP-induced autophosphorylation activity of RIPK2 in cells. RT-PCRCell Line: BMDMs or THP-1 cells Concentration: 500 nM Incubation Time: 0 hour, 2 hours, 4 hours, 8 hours Result: Blocked MDP-induced transcription of the inflammatory mediators TNF and interleukin-6 (IL-6) in BMDMs. And reduced mRNA levels of NF-kB targets in THP-1 cells. In Vivo WEHI-345 (20 mg/kg; intraperitoneal injection; twice daily; for 6 days; C57BL/6 male mice) treatment reduces disease score, inflammatory infiltrate, histological score and recruitment of dendritic cells to the site of inflammation. And improves body weight and reduces cytokine and chemokine levels, indicating an overall improvement of the condition in experimental autoimmune encephalomyelitis (EAE)-induced wild-type C57Bl/6 mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6 male mice (8-week-old) Dosage: 20 mg/kg Administration: Intraperitoneal injection; twice daily; for 6 days Result: Reduced disease score, inflammatory infiltrate, histological score and recruitment of dendritic cells to the site of inflammation. And improved body weight and reduced cytokine and chemokine levels. Form:Solid IC50& Target:IC 50 : 0.13 μM (RIPK2 kinase)

WEHI-345 是一种强效的选择性 RIPK2 激酶抑制剂，IC50 为 0.13 μM，可延缓 RIPK2 泛素化和 NF-κB 在寡聚域（NOD）刺激下的激活。

1354825-58-3

C22H23N7O

401.46 g/mol

56602554

CC1=CC=C(C=C1)C2=NN(C3=NC=NC(=C23)N)C(C)(C)CNC(=O)C4=CC=NC=C4

N-[2-[4-amino-3-(4-methylphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]-2-methylpropyl]pyridine-4-carboxamide

1S/C22H23N7O/c1-14-4-6-15(7-5-14)18-17-19(23)26-13-27-20(17)29(28-18)22(2,3)12-25-21(30)16-8-10-24-11-9-16/h4-11,13H,12H2,1-3H3,(H,25,30)(H2,23,26,27)

LEBSTCDZKUSVOY-UHFFFAOYSA-N

CC1=CC=C(C=C1)C2=NN(C3=NC=NC(=C23)N)C(C)(C)CNC(=O)C4=CC=NC=C4

56602554

DMSO : 25 mg/mL (62.27 mM; Need ultrasonic)

2

6

5

401.196 Da

401.196 Da

112.000 Ų

30

0

586.000

0

1

2.300